Risperdal lawsuits have proliferated in the past few decades. Plaintiffs claim that Johnson & Johnson, maker of the next creation anti-psychotic medication, hid serious unwanted effects, diabetes and gynecomastia (the enlargement of breasts in men ), and encouraged its use in unapproved conditions. The FDA accepted Risperdal for use by adults from 1993, however, it wasn’t until 2006 that the use was authorized for kids. Risperdal’s packaging has been updated in 2006 to state that 2.3 percent of male teens developed gynecomastia.
Johnson & Johnson was also found to have distributed Risperdal for use with older patients, a second unapproved use of this medication. The box also cautions that the drug isn’t approved for use in patients using dementia-related psychosis. Allegations that Johnson & Johnson promoted the drug aggressively to be used by kids as early as 1994 led to a U.S. Department of Justice analysis and the subsequent payment of enormous fines. While doctors are free to prescribe medication for off-label functions, the medication might not be promoted for such use by producer.
The Status of Risperdal Lawsuits
There were 6,082 Risperdal lawsuits pending in the Philadelphia Court of Common pleas, as of September 2017. That number had increased by more than 500 since early June. There have been a number of settlements and trials in Risperdal lawsuits, including one $70 million verdict. Pennsylvania has been a famous venue for complex tort litigation. That tendency will soon come to a conclusion as a consequence of a June Supreme Court decision that stated that either plaintiffs or defendants must have some significant connection to the trial venue (BRISTOL-MYERS SQUIBB CO. v. SUPERIOR COURT OF CALIFORNIA, SAN FRANCISCO COUNTY, ET AL.) In
August 53 Risperdal cases were disregarded in Missouri for this reason. Johnson& Johnson hasn’t yet suggested whether the business will seek out similar dismissals in Pennsylvania.
The FDA approved Risperdal to treat the following conditions:
- Schizophrenia in adults and adolescents
- Bipolar disorder in adults and adolescents
- Autism spectrum disorder in children and adolescents
Off-label refers to uses that are not approved by the FDA. Risperdal has been prescribed off-label to treat conditions including: